BTMD تصريحات هيئة الأوراق المالية والبورصات - biote Corp.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1819253

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to biote Corp.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
August 6, 2025	EX-99.1	Biote Reports Second Quarter 2025 Financial Results Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote Reports Second Quarter 2025 Financial Results Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights • Revenue of $48.
August 6, 2025	8-K	FORM 8-K Item 2.02. Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 biote Corp. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40128 85-1791125 (State or Other Jurisdiction of Incorporation) (Commission File Number
June 9, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
June 9, 2025	EX-99.1	Biote Names Rich Barrera to Board of Directors Exhibit 99.1 Biote Names Rich Barrera to Board of Directors IRVING, TX – June 9, 2025 - biote Corp.(NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. “We are pleased to welcome Rich Barrera
June 5, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
May 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 biote Corp. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
May 9, 2025	EX-10.1	Non-Employee Director Compensation Policy. Exhibit 10.1 biote Corp. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following Jan
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
May 7, 2025	8-K	FORM 8-K Item 2.02. Results of Operations and Financial Condition. Item 2.05 Costs Associated with Exit or Disposal Activities. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 biote Corp. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40128 85-1791125 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
May 7, 2025	EX-99.1	Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights • Revenue of $49.
May 5, 2025	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 24, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
April 9, 2025	S-8	PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT SIGNATURES POWER OF ATTORNEY As filed with the Securities and Exchange Commission on April 9, 2025 Registration No.
April 9, 2025	POS AM	Power of Attorney (included on the signature page to this registration statement). Table of Contents As filed with the Securities and Exchange Commission on April 9, 2025.
April 9, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP.
April 3, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
April 3, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
March 17, 2025	EX-99.1	2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Lit Exhibit 99.1 Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of BioTE Holdings, LL
March 17, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
March 14, 2025	EX-4.1	Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you and is qualified by reference to our second amended and restated certificate of incorporation (t
March 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K 8 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Cor
March 14, 2025	EX-10.9	Consulting Agreement, dated January 30, 2025, by and between BioTE Medical, LLC and Teresa S. Weber (d/b/a ProTech & Associates). Exhibit 10.9 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. CONSULTING AGREEMENT Execution Date: January 30, 2025 This Consulting Agreement (the “Agreement”) is executed as of the Execution Date forth above by a
March 14, 2025	EX-10.8	Transition and Separation Agreement, dated January 30, 2025, by and between BioTE Medical, LLC and Teresa S. Weber. Exhibit 10.8 January 30, 2025 Via Email Teresa S. Weber [email protected] Re: Transition and Retirement Agreement Dear Terry: This letter sets forth the substance of the transition and separation agreement (the “Agreement”) that BioTE Medical, LLC (the “Company”) is offering to you to aid in your transition. 1. Transition and Separation. By executing this Agreement, you agree that your service
March 14, 2025	EX-10.11	Employment Agreement, effective February 1, 2025, by and between BioTE Medical, LLC and Bret Christensen. Exhibit 10.11 January 29, 2025 Mr. Bret Christensen (via e-mail) Re: Offer of Employment Dear Bret: I am pleased to offer you an initial position with BioTE Medical, LLC (the “Company”), as its Chief Executive Officer (“CEO”) working from the Company’s Dallas, Texas, office. Of course, the Company may change your position, duties, and work location from time to time in its discretion. For purposes
March 14, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 BIOTE CORP. INSIDER TRADING POLICY Introduction During the course of your relationship with biote Corp. (the “Company”), you may receive important material information that is not yet publicly available (“inside information” or “material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships with. Material n
March 14, 2025	EX-10.1	Non-Employee Director Compensation Policy Exhibit 10.1 biote Corp. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following Jan
March 12, 2025	EX-99.1	Biote Reports Fourth Quarter and Full Year 2024 Financial Results Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Exhibit 99.1 Biote Reports Fourth Quarter and Full Year 2024 Financial Results Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook IRVING, TX – March 12, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financi
March 12, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
January 30, 2025	EX-99.1	Biote Announces CEO Retirement and Succession Plan Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company’s Board of Directors Exhibit 99.1 Biote Announces CEO Retirement and Succession Plan Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company’s Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director IRVING, TX – January 30, 2025 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care th
January 30, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
November 13, 2024	424B3	biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 22 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 33
November 13, 2024	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 19 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr
November 12, 2024	EX-10.2	Lease Agreement, dated as of September 17, 2024, by and between ES 432-434 Industrial, LLC as Landlord and F.H. Investments, Inc. d/b/a Asteria Health as Tenant. Exhibit 10.2 LEASE AGREEMENT ES 432-434 INDUSTRIAL, LLC Landlord AND F.H. INVESTMENTS, INC. d/b/a ASTERIA HEALTH Tenant AT 432 Industrial Lane Birmingham, AL 35211 i LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made by and between ES 432-434 INDUSTRIAL, LLC, a Delaware limited liability company (“Landlord”), and F.H. INVESTMENTS, INC., an Alabama corporation, d/b/a ASTERIA HEALTH (“Tenan
November 12, 2024	SC 13G/A	BTMD / biote Corp. / Bandera Partners LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga208706btmd11122024.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 biote Corp. (Name of Issuer) Class A common stock, par value $
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
November 12, 2024	EX-99.1	Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Exhibit 99.1 Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages IRVING, TX – November 12, 2024 – Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormo
November 12, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numb
August 9, 2024	424B3	biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock 424B3 1 resales-1prosuppno2.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 21 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our regi
August 9, 2024	EX-10.6	Second Amendment to Credit agreement, dated as of June 26, 2024, by and among BioTE Medical, LLC, BioTE Holdings, LLC, other guarantors party therein, the lenders party therein, and Truist Bank as the Administrative Agent. Exhibit 10.6 Execution Version SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of June 26, 2024 (the “Second Amendment Effective Date”), is entered into by and among BIOTE MEDICAL, LLC, a Texas limited liability company (the “Borrower”), BIOTE HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), the other Guarantors party her
August 9, 2024	EX-10.3	Separation Agreement, by and between BioTE Medical, LLC and Mary Puncochar, dated July 3, 2024. Exhibit 10.3 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This is a Confidential Separation Agreement and General Release of Claims (“Agreement”) by and between Mary Puncochar (“Employee”) and BioTE Medical, LLC, a Texas limited liability company (together with its affiliates, parents, and subsidiaries the “Company”). Employee and Company collectively are referred to herein as t
August 9, 2024	EX-10.5	First Amendment and Waiver to Credit agreement, dated as of April 26, 2024, by and among BioTE Medical, LLC, BioTE Holdings, LLC, other guarantors party therein, the lenders party therein, and Truist Bank as the Administrative Agent. Exhibit 10.5 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT AND WAIVER This FIRST AMENDMENT TO CREDIT AGREEMENT AND WAIVER (this “Agreement”), dated as of April 26, 2024 (the “First Amendment Effective Date”), is entered into by and among BIOTE MEDICAL, LLC, a Texas limited liability company (the “Borrower”), BIOTE HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), the other
August 9, 2024	EX-10.2	Settlement Agreement between the Company and Marci M. Donovitz, dated June 28, 2024. Exhibit 10.2 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings
August 9, 2024	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 18 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
August 8, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
August 8, 2024	EX-99.1	Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Exhibit 99.1 Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, TX – August 8, 2024 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic w
July 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 biote Corp. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
July 3, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
June 21, 2024	EX-99.1	Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares EX-99.1 Exhibit 99.1 Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares IRVING, TX – June 20, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a b
June 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2024 biote Corp. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
May 24, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
May 10, 2024	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 17 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr
May 10, 2024	EX-10.1	Settlement Agreement between the Company and Dr. Gary S. Donovitz, dated April 23, 2024 (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40128) filed with the SEC on May 10, 2024). [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. EXHIBIT 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings
May 10, 2024	424B3	biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 20 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 33
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
May 10, 2024	EX-10.1	Settlement Agreement between the Company and Dr. Gary S. Donovitz, dated April 23, 2024. [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. EXHIBIT 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings
May 10, 2024	EX-10.1	Settlement Agreement between the Company and Dr. Gary S. Donovitz, dated April 23, 2024. [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. EXHIBIT 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is made by and among biote Corp. (“Biote”), BioTE Medical, LLC (“Medical”), BioTE Holdings
May 7, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 7, 2024	EX-99.1	Biote Reports First Quarter 2024 Financial Results Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second h Exhibit 99.1 Biote Reports First Quarter 2024 Financial Results Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth IRVING, TX – May 7, 2024—Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of
April 29, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 23, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
April 29, 2024	EX-99.1	Biote Announces Definitive Settlement with Founder Company to repurchase all of Founder’s 18.4 million shares at $4.17 per share Exhibit 99.1 Biote Announces Definitive Settlement with Founder Company to repurchase all of Founder’s 18.4 million shares at $4.17 per share IRVING, TX – April 29, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered int
April 11, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 11, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 9, 2024	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus relates to the resale of up to 5,000,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (the “Class A common stock”), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Selling Securityholder”)
April 9, 2024	424B3	biote Corp. Up to 58,565,824 Shares of Class A Common Stock Up to 62,289,796 Shares of Class A Common Stock Offered by the Selling Securityholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. Up to 58,565,824 Shares of Class A Common Stock and Up to 62,289,796 Shares of Class A Common Stock Offered by the Selling Securityholders This prospectus relates to the issuance by us of an aggregate of up to 58,565,824 shares of Class A Common Stock issuable to the Members (as defined below) upo
April 3, 2024	S-8	As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No.
April 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP.
April 1, 2024	EX-10.22	Employment Agreement, effective May 30, 2023, by and between BioTE Medical, LLC and Mary Puncochar. EX-10.22 Exhibit 10.22 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Mary Puncochar (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of May 30, 2023 (“Effective Date”). WHEREAS, Executive is employed by the Company as its Chief Commercial Officer (“CCO”); WHEREAS, the Company desires to continue to employ Executive and, in con
April 1, 2024	EX-10.1	Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 10.1 to the Company’s Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-265714) filed with the SEC on April 1, 2024). Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following January 1, 2024
April 1, 2024	POS AM	As filed with the Securities and Exchange Commission March 29, 2024. Registration No. 333-266433 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECUR Table of Contents As filed with the Securities and Exchange Commission March 29, 2024.
April 1, 2024	EX-10.22	Employment Agreement, effective May 30, 2023, by and between BioTE Medical, LLC and Mary Puncochar. EX-10.22 Exhibit 10.22 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Mary Puncochar (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of May 30, 2023 (“Effective Date”). WHEREAS, Executive is employed by the Company as its Chief Commercial Officer (“CCO”); WHEREAS, the Company desires to continue to employ Executive and, in con
April 1, 2024	EX-10.1	Non-Employee Director Compensation Policy. EX-10.1 Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following January
April 1, 2024	EX-10.23	Change in Employment Status, effective March 10, 2024, by and between BioTE Medical, LLC and Mary Puncochar. EX-10.23 Exhibit 10.23 March 3, 2024 Mary Puncochar Re: Change in Employment Status Dear Mary: As discussed, you and Biote® Medical, LLC (the “Company”) have mutually agreed to change your status from a full-time employee to a part-time employee and adjusting your role and responsibilities, accordingly. This letter agreement (the “Agreement”) sets forth the terms of your modified role, compensatio
April 1, 2024	POS AM	Power of Attorney (Included on signature page hereto). Table of Contents As filed with the Securities and Exchange Commission March 29, 2024.
April 1, 2024	EX-10.23	Change in Employment Status, effective March 10, 2024, by and between BioTE Medical, LLC and Mary Puncochar. EX-10.23 Exhibit 10.23 March 3, 2024 Mary Puncochar Re: Change in Employment Status Dear Mary: As discussed, you and Biote® Medical, LLC (the “Company”) have mutually agreed to change your status from a full-time employee to a part-time employee and adjusting your role and responsibilities, accordingly. This letter agreement (the “Agreement”) sets forth the terms of your modified role, compensatio
March 15, 2024	EX-97.1	biote Corp. Incentive Compensation Recoupment Policy. Exhibit 97.1 biote Corp. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of biote Corp., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing
March 15, 2024	EX-10.21	Transition Agreement, effective January 11, 2024, by and between BioTe Medical, LLC and Samar Kamdar (Incorporated by reference to Exhibit 10.21 to the Company’s Annual Report on Form 10-K (File No. 001-40128) filed with the SEC on March 15, 2024). Exhibit 10.21 January 8, 2024 Samar Kamdar 7042 Coronado Avenue Dallas, TX 75214 Re: Transition Agreement Dear Samar: This letter sets forth the substance of the Transition Agreement (the “Agreement”) which BioTE Medical, LLC (the “Company”) is offering to you to aid in your employment transition. 1. Transition Period. As discussed, if you execute and return this Agreement by January 29, 2024 then
March 15, 2024	EX-10.20	Employment Agreement, effective January 8, 2024, by and between BioTE Medical, LLC and Robert C. Peterson (Incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K (File No. 001-40128) filed with the SEC on March 15, 2024). Exhibit 10.20 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Robert Peterson (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of January 8, 2024 (“Effective Date”). WHEREAS, Executive shall be employed by the Company as its Chief Financial Officer (“CFO”); WHEREAS, the Company desires to employ Executive and, in connection ther
March 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K 8 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Cor
March 15, 2024	EX-4.1	Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you and is qualified by reference to our second amended and restated certificate of incorporation (t
March 14, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
March 14, 2024	EX-99.1	2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Lit Exhibit 99.1 Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of BioTE Holdings, LL
March 12, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
March 12, 2024	EX-99.1	Biote Reports Fourth Quarter and Full Year 2023 Financial Results Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase Exhibit 99.1 Biote Reports Fourth Quarter and Full Year 2023 Financial Results Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders’ shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance, with an acceleration i
February 21, 2024	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 19 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio
February 21, 2024	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 16 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). T
February 20, 2024	EX-99.1	Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share Exhibit 99.1 Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share IRVING, TX – February 20, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimiza
February 20, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numb
February 14, 2024	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment SC 13G/A 1 d10973642a13g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* biote Corp. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
February 13, 2024	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / Boston Partners - ROBECO INVESTMENT MANAGEMENT INC. Passive Investment SC 13G/A 1 btmda121324.htm ROBECO INVESTMENT MANAGEMENT INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biote Corp (Name of Issuer) Common Stock (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate
February 13, 2024	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / Bandera Partners LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga108706btmd02142024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 biote Corp. (Name of Issuer) Class A common stock, par value $
February 12, 2024	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / LMR Partners LLP Passive Investment SC 13G/A 1 formsc13ga-biote.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* biote Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the app
January 25, 2024	EX-99.1	Biote Announces $20 Million Share Repurchase Authorization Exhibit 99.1 Biote Announces $20 Million Share Repurchase Authorization IRVING, TX – January 25, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the
January 25, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
January 17, 2024	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 15 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr
January 17, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
January 17, 2024	EX-99.1	Biote Provides Preliminary 2023 Results and Initial 2024 Guidance Exhibit 99.1 Biote Provides Preliminary 2023 Results and Initial 2024 Guidance IRVING, TX – January 17, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below p
January 17, 2024	EX-99.2	Biote to Purchase Asteria Health Strategic and accretive transaction enables vertical integration of hormone product manufacturing Exhibit 99.2 Biote to Purchase Asteria Health Strategic and accretive transaction enables vertical integration of hormone product manufacturing IRVING, TX – January 17, 2024 – biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive a
January 17, 2024	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 18 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat
January 11, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number
January 11, 2024	EX-99.1	Biote Names Robert Peterson as Chief Financial Officer Exhibit 99.1 Biote Names Robert Peterson as Chief Financial Officer IRVING, TX — January 11, 2024 — biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr
November 14, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 14 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr
November 14, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 17 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
November 7, 2023	EX-99.1	Biote Reports Third Quarter 2023 Financial Results Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance Exhibit 99.1 Biote Reports Third Quarter 2023 Financial Results Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance IRVING, TX – November 7, 2023 – Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 3
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
October 5, 2023	CORRESP	Year Ended 1875 W. Walnut Hill Ln, #100 Irving, TX 75038 October 5, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Eric Atallah Tara Harkins RE: Biote Corp. Form 10-K for the Year Ended December 31, 2022 Filed March 29, 2023 Form 8-K Filed August 10, 2023 File No. 001-40128 Ladies and G
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
August 11, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 13 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pr
August 11, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 16 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 biote Corp. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number
August 10, 2023	EX-99.1	Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men’s Health Categori EX-99.1 Exhibit 99.1 Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men’s Health Categories IRVING, TX – August 10, 2023 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delive
June 23, 2023	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
June 15, 2023	SC 13D	US0906831039 / BIOTE CORP 0.00000000 / 325 CAPITAL LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 biote Corp. (Name of Issuer) Common Stock, $0.0001 par value Common Stock, Par Value $0.001 per share (Title of Class of Securities) 090683103 (CUSIP Number) Michael Braner 325 Capital LLC 757 Third Avenue, 20th Floor New York, NY 10017 646-774-2904 (Name, Address and Tele
June 15, 2023	EX-99.1	Joint Filing Agreement EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of biote Corp., a Delaware corporation. This Joint Filin
June 13, 2023	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 13, 2023 with respect to the Class A common stock, par value $0.0001 per share, of biote Corp., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1)
June 13, 2023	SC 13G	US0906831039 / BIOTE CORP 0.00000000 / Bandera Partners LLC - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 biote Corp. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) June
June 9, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 biote Corp. (Exact n 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
June 9, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 12 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). T
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 biote Corp. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
June 9, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 15 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio
June 9, 2023	EX-10.1	Amendment No.1 to Warrant Agreement, dated as of June 8, 2023, by and between the Company and Continental Stock Transfer & Trust Company (Incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K (File No. 001-40128) filed with the SEC on June 8, 2023). EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This Amendment (this “Amendment”) is made as of June 8, 2023 by and between biote Corp., a Delaware corporation (the “Company”) (f/k/a Haymaker Acquisition Corp. III), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that certain Warrant Agreement
June 9, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) biote Corp. (Name of Subject Company and Filing Per SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) biote Corp. (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Shares of Class A Common Stock (Title of Class of Securities) 090683111 (CUSIP Number of Class of Securiti
June 9, 2023	EX-99.1	Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants EX-99.1 Exhibit 99.1 Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX – June 8, 2023 - Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced (i) offer to each
June 7, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 11 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). T
June 7, 2023	424B3	biote Corp. 5,217,392 Shares of Class A Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. 5,217,392 Shares of Class A Common Stock This is a public offering of shares of our Class A common stock, par value $0.0001 per share (the “Class A common stock”). The selling stockholder identified in this prospectus is offering 5,217,392 shares of Class A common stock. The selling stockhol
June 7, 2023	EX-1.1	Underwriting Agreement, dated as of June 5, 2023, by the among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein (Incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K (File No. 001-40128) filed with the SEC on June 7, 2023). U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains
June 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2023 biote Corp. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
June 7, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 14 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio
June 6, 2023	CORRESP	BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 June 6, 2023 VIA EDGAR CORRESP BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 June 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christina Chalk and Blake Grady RE: biote Corp. Registration Statement on Form S-4 (File No. 333-271782) Acceleration Request Requested Date: June 7, 2023 Requested Time: 5:00 P.M. Ea
May 23, 2023	CORRESP	Cooley LLP 500 Boylston Street, 14th Floor Boston, MA 02116-3736 t: (617) 937-2300 f: (617) 937-2400 cooley.com CORRESP Ryan Sansom +1 617 937 2335 [email protected] May 23, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office Mergers & Acquisitions 100 F Street, N.E. Washington, DC 20549 Attn: Christina Chalk and Blake Grady Re: biote Corp. Schedule TO-I filed May 9, 2023 File No. 005-92341 Form S-4 filed May 9, 2023 Form S-4/A filed May 16, 2023 File No. 333-271782 Dear Ms.
May 23, 2023	S-4/A	As filed with the Securities and Exchange Commission on May 23 , 2023 Registration No. 333-271782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1 Table of Contents As filed with the Securities and Exchange Commission on May 23 , 2023 Registration No.
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2023 biote Corp. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (
May 16, 2023	EX-99.4	Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.4 Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN
May 16, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 13 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part
May 16, 2023	S-4/A	As filed with the Securities and Exchange Commission on May 1 6 , 2023 Registration No. 333-271782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF Table of Contents As filed with the Securities and Exchange Commission on May 1 6 , 2023 Registration No.
May 16, 2023	EX-10.23	Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. EX-10.23 Exhibit 10.23 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of [●], 2023, is entered into by and among biote Corp., a Delaware corporation (the “Company”), each of the persons listed on Schedule A hereto (each, a “Public Warrant Holder”) and each of the persons listed on Schedule B hereto (each, a “Private Warrant Holder” and, together with th
May 16, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 10 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration
May 16, 2023	EX-99.1	Form of Letter of Transmittal and Consent. EX-99.1 Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JUNE 7, 2023, OR SUCH LATER TIME AND DAT
May 16, 2023	EX-99.3	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.3 Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TI
May 15, 2023	DEL AM	May 12, 2023 DEL AM May 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: biote Corp. Registration Statement on Form S-4 (File No. 333-271782) Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-4 (File No. 333-271782) filed by biote Corp. on May 9, 2023 (the “Registration Statement”). Pursuant to
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
May 10, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 9 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). Th
May 10, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 12 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registratio
May 10, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 biote Corp. (Exact na 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number
May 9, 2023	EX-10.23	Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. EX-10.23 Exhibit 10.23 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of [●], 2023, is entered into by and among biote Corp., a Delaware corporation (the “Company”), each of the persons listed on Schedule A hereto (each, a “Public Warrant Holder”) and each of the persons listed on Schedule B hereto (each, a “Private Warrant Holder” and, together with th
May 9, 2023	EX-99.1	Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men’s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance EX-99.1 Exhibit 99.1 Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men’s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance IRVING, TX – May 9, 2023—Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today
May 9, 2023	EX-FILING FEES	Youâve Exceeded the SECâs Traffic Limit EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) BIOTE CORP.
May 9, 2023	EX-99.1	Form of Letter of Transmittal and Consent. EX-99.1 Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JUNE 7, 2023, OR SUCH LATER TIME AND DAT
May 9, 2023	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 biote Corp. (Name of Subject Company and Filing Person (Issuer)) Warr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 biote Corp. (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Shares of Class A Common Stock (Title of Class of Securities) 090683111 (CUSIP Number of Class of Securities) Teresa S. Weber Chief Ex
May 9, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) BIOTE CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Fo
May 9, 2023	S-4	Power of Attorney (Included on signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on May 9, 2023 Registration No.
May 9, 2023	EX-99.4	Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.4 Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 biote Corp. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 9, 2023	EX-99.2	Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants EX-99.2 Exhibit 99.2 Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX – May 9, 2023 - Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (th
May 9, 2023	EX-99.3	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.3 Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Class A Common Stock of biote Corp. for Shares of Class A Common Stock of biote Corp. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TI
May 9, 2023	EX-99.2	Form of Notice of Guaranteed Delivery. EX-99.2 Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF BIOTE CORP. Pursuant to the Prospectus/Offer to Exchange dated May 9, 2023 Instructions for Use Unless defined herein, terms used in this Notice of Guaranteed Delivery shall have definitions set forth in the Prospectus/Offer to Exchange dated May 9, 2023. This Notice of Guaranteed Delivery, or one substantially in the form hereof, m
April 24, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP.
April 24, 2023	S-8	Power of Attorney (contained on the signature page hereto). S-8 As filed with the Securities and Exchange Commission on April 24, 2023 Registration No.
April 14, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 d381833ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
April 13, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus relates to the resale of up to 5,000,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (the “Class A common stock”), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Selling Securityho
April 13, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Offered by the Selling Securityholders 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. Up to 72,069,990 Shares of Class A Common Stock and Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Offered by the Selling Securityholders This prospectus relates to the issuance by us of an aggregate of up to 72,069,990 shares of our Class A Common Stock, $0.0001 pa
April 6, 2023	POS AM	As filed with the Securities and Exchange Commission April 5 , 2023. Registration No. 333-265714 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECUR As filed with the Securities and Exchange Commission April 5 , 2023. Registration No. 333-265714 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 biote Corp. (Exact name of Registrant as specified in its charter) Delaware 2833 85-1791125 (State or other jurisdiction of incorpor
April 6, 2023	POS AM	As filed with the Securities and Exchange Commission April 5, 2023. Registration No. 333-266433 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST- EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECUR As filed with the Securities and Exchange Commission April 5, 2023. Registration No. 333-266433 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST- EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 biote Corp. (Exact name of Registrant as specified in its charter) Delaware 2833 85-1791125 (State or other jurisdiction of incorpor
March 30, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro
March 30, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 11 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat
March 30, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 10 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration stat
March 30, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 8 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro
March 29, 2023	EX-10	Non-Employee Director Compensation Policy. (Incorporated by reference to Exhibit 10.1 to the Company’s Annual Report on Form 10-K (File No. 001-40128) filed by the Company with the SEC on March 29, 2023). EX-10 3 btmd-ex101.htm EX-10.1 Exhibit 10.1 biote Corp. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board
March 29, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO.
March 29, 2023	EX-4	Description of the Registrant’s Securities. Exhibit 4.3 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you, and is qualified by reference to our Charter, the Bylaws, the A&R IRA and the Warrant Agreement
March 29, 2023	EX-10	biote Corp. 2022 Equity Incentive Plan. (Incorporated by reference to Exhibit 10.17 to the Company’s Annual Report on Form 10-K (File No. 001-40128) filed by the Company with the SEC on March 29, 2023). Exhibit 10.17 biote Corp. 2022 Equity Incentive Plan Adopted by the Board of Directors: May 26, 2022 Approved by the Stockholders: May 24, 2022 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affilia
March 29, 2023	10-K	Form 10-K 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
March 29, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (AMENDMENT NO.
March 28, 2023	EX-99.1	Biote Reports Fourth Quarter and Full Year 2022 Financial Results Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trad EX-99.1 Exhibit 99.1 Biote Reports Fourth Quarter and Full Year 2022 Financial Results Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering IRVING, TX – March 28, 2023—Biote (NASDAQ: BTMD), a leading solutions pro
March 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 biote Corp. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
March 24, 2023	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). Th
March 24, 2023	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 9 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration
March 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2023 biote Corp. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2023 biote Corp. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2023 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numb
February 22, 2023	EX-3.1	Amended and Restated Bylaws of biote Corp. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-40128) filed with the SEC on February 22, 2023). EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF biote CORP. (THE “CORPORATION”) February 21, 2023 ARTICLE I. OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corpora
February 17, 2023	SC 13G	US0906831039 / BIOTE CORP 0.00000000 / Roystone Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2023	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / LMR Partners LLP - SC 13G/A Passive Investment SC 13G/A 1 d432263dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* biote Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check
February 14, 2023	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / GLAZER CAPITAL, LLC Passive Investment SC 13G/A 1 btmd20221231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 biote Corporation (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 090683103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 14, 2023	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 d432263dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fil
February 7, 2023	SC 13G	US0906831039 / BIOTE CORP 0.00000000 / Boston Partners - ROBECO INVESTMENT MANAGEMENT INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Biote Corp (Name of Issuer) Common Stock (Title of Class of Securities) 090683103 (CUSIP Number) January 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-
February 3, 2023	SC 13G/A	US0906831039 / BIOTE CORP 0.00000000 / BlueCrest Capital Management Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* biote Corp.** (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) 31 December 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r
January 6, 2023	424B4	biote Corp. 7,391,305 Shares of Common Stock 424B4 1 d344838d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-268748 PROSPECTUS biote Corp. 7,391,305 Shares of Common Stock This is a public offering of shares of our Class A common stock, par value $0.0001 per share (the “Class A common stock”). The selling stockholders identified in this prospectus are offering 7,391,305 shares of Class A common stock.
January 3, 2023	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 7,391,305 biote Corp. Class A Common Stock UNDERWRITING AGREEMENT January [?], 2023 TRUIST SECURITIES, INC. 3333 Peachtree Road, NE, 11th Floor Atlanta, Georgia 30326 COWEN AND COMPANY, LLC 599 Lexington Ave., 25th floor New York, NY 10022 ROTH CAPITAL PARTNERS, LLC 888 San Clemente Dr. Newport Beach, CA 92660 As Representatives of the several Underwriters named in Schedule I attached
January 3, 2023	S-1/A	As filed with the Securities and Exchange Commission January 3, 2023 Table of Contents As filed with the Securities and Exchange Commission January 3, 2023 Registration No.
January 3, 2023	CORRESP	BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 January 3, 2023 VIA EDGAR CORRESP 1 filename1.htm BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 January 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara RE: biote Corp. Registration Statement on Form S-1 (File No. 333-268748) Acceleration Request Requested Date: January 3, 2023 Requested Time: 4:30 P.
January 3, 2023	CORRESP	* * * [Signature Page Follows] January 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
December 12, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) biote Corp.
December 12, 2022	S-1	Power of Attorney (included on signature page hereto). Table of Contents As filed with the Securities and Exchange Commission December 9, 2022 Registration No.
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
November 14, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 1 bioteresales-1prosup.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 8 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which
November 14, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 8 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state
November 14, 2022	EX-10.3	Transition Agreement, effective August 31, 2022, by and between BioTE Medical, LLC and Robbin Gibbins. (Incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40128) filed by the Company with the SEC on November 14, 2022). Exhibit 10.3 August 26, 2022 (as modified on August 31, 2022) Robbin Gibbins Re: Transition Agreement Dear Robb: This letter sets forth the substance of the Transition Agreement (the ?Agreement?) which BioTE Medical, LLC (the ?Company?) is offering to you to aid in your employment transition. 1. Transition Period. As discussed, if you execute and return this Agreement by September 7, 2022 then you
November 14, 2022	EX-10.1	Employment Agreement, effective July 15, 2022, by and between BioTE Medical, LLC and Samar Kamdar (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40128) filed by the Company with the SEC on November 14, 2022). Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into by and between Samar Kamdar (?Executive?) and BioTE Medical, LLC (the ?Company?), and effective as of July 25, 2022 (?Effective Date?). WHEREAS, Executive is employed by the Company as its Chief Financial Officer (?CFO?); WHEREAS, the Company desires to continue to employ Executive and, in connection ther
November 14, 2022	EX-10.2	Amendment to Employment Agreement, effective August 24, 2022, by and between BioTE Medical, LLC and Samar Kamdar (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40128) filed by the Company with the SEC on November 14, 2022). Exhibit 10.2 Amendment to Employment Agreement This Amendment to Employment Agreement (the ?Amendment?) is entered into this 24th day of August 2022 (the ?Effective Date?), by and between Samar Kamdar (the ?Executive?) and BioTE Medical, LLC (the ?Company?). Recitals A. The Company and Executive have entered into that certain Employment Agreement dated as of July 25, 2022 (the ?Employment Agreemen
November 14, 2022	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 1 bioteelocs-1prosupp.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
November 8, 2022	EX-99.1	Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance Exhibit 99.1 Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX ? November 8, 2022 - Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced financial results for the thir
November 7, 2022	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro
November 7, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 1 d387411d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms
November 7, 2022	EX-99.1	Biote Appoints Debby Morris to Board of Directors Exhibit 99.1 Biote Appoints Debby Morris to Board of Directors IRVING, TX ? November 7, 2022 ? biote Corp. (Nasdaq: BTMD) (?Biote? or the ?Company?), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote?s Board of Directors. Ms. Morris brings more than three decades of experience in directing fi
November 7, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
October 12, 2022	SC 13G	US0906831039 / BIOTE CORP 0.00000000 / LMR Partners LLP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* biote Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 090683103 (CUSIP Number) October 6, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule
October 11, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Numbe
October 11, 2022	EX-99.1	Biote Releases Updated Corporate Presentation for October 2022 Exhibit 99.1 Biote Releases Updated Corporate Presentation for October 2022 October 10, 2022 IRVING, Texas?(BUSINESS WIRE)?Oct. 10, 2022?biote Corp. (Nasdaq: BTMD) (?Biote? or the ?Company?), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time in communicatio
August 25, 2022	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro
August 25, 2022	EX-99.1	Biote Announces Approval to Relist on The Nasdaq Stock Market Company will resume trading under its existing symbols “BTMD” and “BTMDW” EX-99.1 Exhibit 99.1 Biote Announces Approval to Relist on The Nasdaq Stock Market Company will resume trading under its existing symbols “BTMD” and “BTMDW” IRVING, TX, August 25, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has appro
August 25, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number
August 25, 2022	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 biote Corp. (Exact name of registrant as specifie 8-A12B 1 d180209d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 biote Corp. (Exact name of registrant as specified in its charter) Delaware 85-1791125 (State of incorporation or organization) (I.R.S. Employer Identification No.)
August 25, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 1 d399424d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms
August 24, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state
August 24, 2022	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-266433). This pro
August 24, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number
August 24, 2022	EX-99.1	Biote Appoints Samar Kamdar as Chief Financial Officer Exhibit 99.1 Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 ? biote Corp. (?Biote? or the ?Company?), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr. Kamdar will oversee Biote?s financial operations with a focus on drivin
August 16, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state
August 16, 2022	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 1 bioteelocs-1prosupp.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated August 9, 2022) biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated August 9, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40128 biote Corp.
August 15, 2022	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Comm
August 15, 2022	EX-99.1	Biote Issues Correction to Second Quarter Operating Loss and Net Income Exhibit 99.1 Biote Issues Correction to Second Quarter Operating Loss and Net Income IRVING, TX, August 15, 2022 ?Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled ?Biote Reports Second Quarter 2022 Financial Results,? issued on August 9, 2022. The other financial results reported in the original pre
August 10, 2022	EX-99.1	Biote Reports Second Quarter 2022 Financial Results Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance Revised Dial-in Information for the Conference Call Exhibit 99.1 Biote Reports Second Quarter 2022 Financial Results Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance Revised Dial-in Information for the Conference Call IRVING, TX, August 9, 2022 ? Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financ
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
August 9, 2022	424B3	biote Corp. Up to 5,000,000 Shares of Common Stock 424B3 1 d385770d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-266433 PROSPECTUS biote Corp. Up to 5,000,000 Shares of Common Stock This prospectus relates to the resale of up to 5,000,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (the “Class A common stock”), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Selling Se
August 3, 2022	EX-99.3	Form of Stock Option Grant Notice (Incorporated by reference to Exhibit 99.3 of the Company’s Registration Statement on Form S-8 filed on August 3, 2022). Exhibit 99.3 BIOTE CORP. STOCK OPTION GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) biote Corp. (the ?Company?), pursuant to the Company?s 2022 Equity Incentive Plan (the ?Plan?), has granted to you (?You,? or ?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth herein, in t
August 3, 2022	EX-99.2	biote Corp. 2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 99.2 of the Company’s Registration Statement on Form S-8 filed on August 3, 2022). Exhibit 99.2 BIOTE CORP. 2022 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 26, 2022 APPROVED BY THE STOCKHOLDERS: MAY 24, 2022 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series o
August 3, 2022	S-8	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 3, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 9 d380602dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 BIOTE CORP. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(6) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2022 Equity Incentive Plan (Class A common stock, $0.
August 3, 2022	CORRESP	BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 August 3, 2022 VIA EDGAR CORRESP 1 filename1.htm BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 August 3, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dorrie Yale RE: biote Corp. Registration Statement on Form S-1 File No. 333-266433 Acceleration Request Requested Date: August 5, 2022 Requested Time: 4:05 P.M. East
August 3, 2022	EX-99.1	biote Corp. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 of the Company’s Registration Statement on Form S-8 filed on August 3, 2022). Exhibit 99.1 BIOTE CORP. 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 26, 2022 APPROVED BY THE STOCKHOLDERS: MAY 24, 2022 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliat
August 3, 2022	EX-99.4	Form of RSU Award Grant Notice (Incorporated by reference to Exhibit 99.4 of the Company’s Registration Statement on Form S-8 filed on August 3, 2022). Exhibit 99.4 BIOTE CORP. RSU AWARD GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) biote Corp. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below in consideration of Participant?s services (the ?RSU Award?). The RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2022 Equity
August 1, 2022	S-1	As filed with the Securities and Exchange Commission July 29, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 biote Corp. (Exact name Table of Contents As filed with the Securities and Exchange Commission July 29, 2022.
August 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) biote Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to
July 28, 2022	EX-10.1	Standby Equity Purchase Agreement, by and between biote Corp. and YA II PN, LTD (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40128) filed by the Company with the SEC on July 28, 2022). Exhibit 10.1 Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this ?Agreement?) dated as of July 27, 2022 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership
July 28, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
July 28, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state
July 19, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the ?Prospectus?), which forms a part of our registration state
July 19, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Offered by the Selling Securityholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS biote Corp. Up to 72,069,990 Shares of Class A Common Stock and Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants Offered by the Selling Securityholders This prospectus relates to the issuance by us of an aggregate of up to 72,069,990 shares of our Class A Common Stock, $0.0001 par valu
July 19, 2022	EX-10.1	Amended and Restated Investor Rights Agreement, dated as of July 19, 2022, by and among the Company, the Members, the Members’ Representative, Haymaker Sponsor III LLC and certain other parties thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40128) filed by the Company with the SEC on July 19, 2022). Exhibit 10.1 Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (as it may be amended, supplemented or restated from time to time in accordance with the terms of this
July 19, 2022	424B3	biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants 424B3 1 d378763d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-265714 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated July 19, 2022) biote Corp. Up to 72,069,990 Shares of Class A Common Stock Up to 67,856,462 Shares of Class A Common Stock Up to 5,566,666 Warrants This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms
July 19, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
July 19, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2022 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number)
July 15, 2022	CORRESP	BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 July 15, 2022 VIA EDGAR BIOTE CORP. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 July 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford and Laura Crotty RE: biote Corp. Registration Statement on Form S-1 File No. 333-265714 Acceleration Request Requested Date: July 19, 2022 Requested Time: 4:05 P.M. Eastern T
July 11, 2022	CORRESP	Cooley LLP 500 Boylston Street, 14th Floor Boston, MA 02116-3736 t: (617) 937-2300 f: (617) 937-2400 cooley.com Ryan Sansom +1 617 937 2335 [email protected] July 11, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Daniel Crawford and Laura Crotty Re: biote Corp. Amendment No. 2 to Registration Statement on Form S-1 Filed June 28, 2022 File No. 333-265714 Dear Mr. Crawford and Ms. Crotty: On behalf of our cli
July 11, 2022	S-1/A	As filed with the Securities and Exchange Commission July 11, 2022. Table of Contents As filed with the Securities and Exchange Commission July 11, 2022.

BTMD / biote Corp. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)